ABSTRACT Obesity and comorbid binge eating are serious health problems for more than 40% of adults across the US.7 Health complications due to obesity comprise more than 20% of the nation’s healthcare budget, and the healthcare costs of individuals with binge eating are $18,152 higher than in obese peers without binge eating.13 The prevalence of binge eating and the substantial burden of healthcare costs highlight the need for treatments that eliminate binge eating and produce weight loss. Despite this, there is a paucity of interventions that address these comorbid conditions. In this Phase 1 project, we seek to build a digital therapeutic (called OTX-401) that will be ready for testing in a large, multi-site, well-powered clinical trial during Phase 2. Positive results will be the critical initial step to facilitating the widespread implementation and commercialization of the digital therapeutic to enhance access to highly personalized obesity and binge eating intervention.

PROJECT NARRATIVE Approximately 80 million adults in the US over the age of 20 have obesity. Among obese adults who seek treatment, more than 25% engage in binge eating; this comorbidity has more severe health outcomes and is more costly to treat than obesity alone. Oui Therapeutics seeks to partner with leading researchers in the field of eating disorders to develop a novel self-guided digital intervention product (called OTX-401) for the treatment of obesity combined with binge eating.